Drug Patent Expirations in January 2014

Drug Patent Expirations for January 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
EPIVIR-HBV Glaxosmithkline lamivudine RE39155*PED Jan 2, 2014
MICARDIS Boehringer Ingelheim telmisartan 5,591,762 Jan 7, 2014
TWYNSTA Boehringer Ingelheim amlodipine besylate; telmisartan 5,591,762 Jan 7, 2014
COMBIPATCH Novartis estradiol; norethindrone acetate 6,024,976 Jan 7, 2014
GLUCOTROL XL Pfizer glipizide 5,591,454 Jan 7, 2014
VIVELLE-DOT Novartis estradiol 6,024,976 Jan 7, 2014
MICARDIS HCT Boehringer Ingelheim hydrochlorothiazide; telmisartan 5,591,762 Jan 7, 2014
RAPAMUNE Pf Prism Cv sirolimus 5,100,899*PED Jan 7, 2014
MINIVELLE Noven estradiol 6,024,976 Jan 7, 2014
ATACAND Astrazeneca candesartan cilexetil 5,534,534*PED Jan 9, 2014
ATACAND HCT Astrazeneca candesartan cilexetil; hydrochlorothiazide 5,534,534*PED Jan 9, 2014
PRECEDEX Hospira dexmedetomidine hydrochloride 4,910,214*PED Jan 15, 2014
SANDOSTATIN LAR Novartis octreotide acetate 5,538,739*PED Jan 23, 2014
XYZAL Ucb Inc levocetirizine dihydrochloride 5,698,558*PED Jan 26, 2014
DULERA Merck Sharp Dohme formoterol fumarate; mometasone furoate 6,677,323 Jan 27, 2014
NORVIR Abbott ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,635,523*PED Jan 30, 2014
KALETRA Abbvie lopinavir; ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,674,882*PED Jan 30, 2014
BETAXON Alcon Pharms Ltd levobetaxolol hydrochloride 5,540,918*PED Jan 30, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.